entertainment -WSS

entertainment

author：hotspot 2025-10-03 00:22:32 - browse：12197

NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.

The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700 million more on the table if certain regulatory and launch milestones are reached.

While Novavax’s stock soared during the pandemic as the vaccine race was underway, the company failed to get its shot authorized in the U.S. market until July 2022, long after the makers of mRNA vaccines had reaped billions in sales. Sales have sputtered along since then, and last year, the Maryland-based company warned that that it may not be able to stay in business.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： At JPM 2024, hospital systems pitch financial strength to investors

entertainment

focus

WSS

Apple Vision Pro: A first look at health apps on the new VR headset

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Medicare Advantage overpayments discussion gets experts fired up

FDA drug safety: Singulair case shows systemic surveillance flaws

Gene therapy denied for Afghan refugee whose father aided U.S.

The lessons of Aduhelm, an Alzheimer's drug that was not to be

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Medicare details structure of new drug price negotiation program

Male doctors called my cancer incurable. A female doctor showed it wasn't

Guidelines to prevent youth baseball injuries need more muscle

A $475,000 price tag for a new cancer drug: crazy or meh?

Medical records are filled with copy

ARCH Venture Partners is raising $3 billion for a life sciences fund

Tori Bowie and the unacceptable rates of Black maternal death

Ascension's ugly legal battle over care for poor patients in Texas

Duchenne breakthrough therapy leaves behind pioneering families

New Ultima Genomics DNA sequencer can read genome for $100

hotspot

Stories you might have missed in 2023: health, science, medicine

Arena BioWorks launches in Cambridge to speed drug discovery

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

FDA drug safety: Singulair case shows systemic surveillance flaws

Quicker fix for pulse oximeters urged during FDA public meeting

Medicare drug price negotiation’s day in court

entertainment

entertainment

focus

hotspot